BRAF、C-KIT、NRAS突变对黑色素瘤脑转移患者的预后价值
该回顾性多中心数据库纳入2006–2015年823例黑色素瘤脑转移患者,分析BRAF、NRAS、C-KIT突变状态与生存的关系。BRAF突变阳性者中位生存13个月,阴性者9个月(P=.02),NRAS和C-KIT突变与生存无显著差异;2006–2015队列中位生存10.0个月,较1985–2005队列的6.7个月改善(P<.01)。
要点
- BRAF突变阳性黑色素瘤脑转移患者中位生存13个月,优于BRAF阴性者的9个月。
- NRAS或C-KIT突变状态与脑转移后生存无显著差异。
- 2006–2015队列中位生存10.0个月,较1985–2005队列的6.7个月改善。
核心结论
- BRAF突变阳性黑色素瘤脑转移患者生存长于BRAF阴性患者。
- 2006–2015年队列总体生存较1985–2005年队列改善。
研究设计与样本
- 回顾性多中心数据库纳入2006–2015年确诊的823例黑色素瘤脑转移患者。
- 分析临床参数、BRAF/NRAS/C-KIT突变状态及治疗与生存的相关性,并与1985–2005年队列比较治疗模式和结局。
主要发现
- 823例中584例(71%)已知BRAF状态,BRAF、NRAS、C-KIT突变率分别为51%、22%、11%。
- 原发诊断至脑转移中位时间32个月,脑转移初始治疗后总中位生存10个月。
- BRAF阳性与阴性患者中位生存分别为13个月和9个月(P=.02)。
- NRAS或C-KIT突变与野生型患者中位生存无显著差异。
- 1985–2005队列与2006–2015队列中位生存分别为6.7个月和10.0个月(P<.01)。
关键数值与推荐
- 全脑放疗使用比例从48%降至26%。
- BRAF阳性患者中71%接受BRAF和/或MEK抑制剂靶向治疗,57%接受靶向治疗、化疗和/或免疫治疗的部分组合。
临床怎么用
- 对黑色素瘤脑转移患者应检测BRAF突变状态以辅助预后判断。
- BRAF阳性患者可考虑接受靶向治疗,但需结合整体治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients. METHODS AND MATERIALS: We created a retrospective multi-institutional database of 823 patients with melanoma and brain metastases diagnosed between 2006 and 2015. Clinical parameters, gene mutation status (BRAF, C-KIT, NRAS), and treatment were correlated with survival. Treatment patterns and outcomes were compared with a prior era (1985-2005). RESULTS: BRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months. MS for BRAF-positive and BRAF-negative patients was 13 months and 9 months, respectively (P=.02). There was no significant difference in MS in patients with or without NRAS or C-KIT mutations. The time from primary diagnosis to brain metastasis did not vary by mutation and was not associated with survival after the diagnosis of brain metastases. MS for the 1985 to 2005 and 2006 to 2015 cohorts was 6.7 months and 10.0 months, respectively (P<.01). Reflecting treatment-trend changes, use of whole-brain radiation therapy decreased from 48% to 26% during this period. Among BRAF-positive patients, 71% received targeted BRAF and/or MEK inhibitors and 57% received some combination of targeted therapy, chemotherapy, and/or immunotherapy. CONCLUSIONS: For melanoma patients with brain metastases, BRAF-positive patients survive longer than BRAF-negative patients and overall survival has improved from 1985-2005 to 2006-2015.
引用
- Sperduto PW, Jiang W, Brown PD, et al. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721890. doi:10.1016/j.ijrobp.2017.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。